Pharmacogenomic study of gemcitabine on the safety and efficacy in patients with metastatic pancreatic cancer (GENESECT study): Analysis of a subpopulation.

• DOI: 10.1200/jco.2024.42.3_suppl.651
• Publication Date: 2024-01-22T21:12:58Z
• Authors: Takashi Yokokawa; Daiki Tsuji; Masahiro Hatori; Kenichi Suzuki; Kazuyoshi Kawakami; Masahiko Nakao; Takuya Yano; Yuichiro Arakawa; Keisuke Matsuo; Yasukata Ohashi; Masato Ozaka; Naoki Sasahira; Yasuhiko Sakata; Yuki Kogure; Shinya Tamaki; Atsushi Wada; Yusuke Taki; Hiroshi Ishii; Kunihiko Itoh; Masakazu Yamaguchi
• Keywords: Univariate analysis; FOLFIRINOX

651 Background: In the GENESECT study, we examined relationships between gemcitabine (GEM) metabolism-related germline genetic polymorphisms (GPs) and treatment efficacy safety. However, no significant GPs were found because approximately 70% of patients treated with nab-paclitaxel, which has a different metabolic process than GEM. present subanalysis including only GEM monotherapy was performed. Methods: Of 159 analyzed in selected. The endpoints carbohydrate antigen 19-9 (CA19-9) response (reduction ≥50% from pretreatment level at 8 weeks), progression-free survival (PFS), overall (OS) relation to viewpoint efficacy, neutropenia ≥Grade 3 thrombocytopenia genes included those encoding transporters enzymes ( SLC29A1, ABCC5, CDA, DCK, RRM1/2), tumor cell proliferation enzyme COX-2). Statistical analysis univariate multivariate logistic regression analyses. significance set 5%. Results: Data 50 analyzed. AA genotype ABCC5 1146A>G (rs7636910) associated significantly higher percentage CA19-9 responses compared AG/GG (52.9% vs 21.2%, p = 0.023), association remained on (OR: 6.255, 0.014). Patients tended be PFS, but this not statistically (HR: 0.464, 0.074). On other hand, there DCK-1205C>T (rs4694362), TT/CT prolonged PFS CC (median, 127 48 days, 0.002), 0.153, 0.028). No OS, presence second-line chemotherapy relevant factor. terms safety, either or thrombocytopenia. Conclusions: results suggest that DCK might related GEM, further research is needed. Clinical trial information: UMIN000012720 .